Slack's (WORK) widely-covered direct listing was hailed as a success. Slack opened on Thursday at $38.50, well above the NYSE's "reference price" of $26, and more than triple its last round less than a year ago. And yet, new public...read more
Atreca, a preclinical biotech developing immunotherapies for solid tumors, raised $125 million by offering 7.4 million shares at $17, the midpoint of the $16 to $18 range. Existing investors had indicated an interest in buying up to $60 million on the IPO...read more
A wave of biotechs are preparing to go public in June, with five on the IPO calendar for this week and four more scheduled for the week of June 24. Two others could soon launch...read more
June's flood of biotech IPOs continues with these 4 deals
June is seeing a wave of biotech IPOs. Five priced last week, and four more are on ...read more
US IPO Weekly Recap: WORK's direct listing works as Slack and 6 others go public
Slack's (WORK) widely-covered direct listing was hailed as a success. Slack opened on Thursday at $38.50, well above the NYSE's "reference price" of $26, and more than triple its last round less than a year ago. And yet, new public...read more
Cancer biotech Atreca prices IPO at $17 midpoint
Atreca, a preclinical biotech developing immunotherapies for solid tumors, raised $125 million by offering 7.4 million shares at $17, the midpoint of the $16 to $18 range. Existing investors had indicated an interest in buying up to $60 million on the IPO...read more
June is getting a flood of biotech IPOs with these 9 deals on the calendar
A wave of biotechs are preparing to go public in June, with five on the IPO calendar for this week and four more scheduled for the week of June 24. Two others could soon launch...read more